🚨 Only a few spots left! 5 expert physicians. 4 interactive stations. 1 hands-on experience. Join Drs. @realarainmd @LAzzaliniMD @Samsayfo @HadyLichaaMD and Mitul Patel at the Next-Generation DEB Decision Lab at #TCT2026. Diagnose. Strategize. Select. Deliver. Register now: tctconference.com/tct-traini…

Delivering Limus. Advancing the conversation on coronary intervention. Join #Cordis at #TCT2026 as experts, @Drroxmehran MD, @AlokeFinn MD, George Adams, MD, David Hildick-Smith, MD, @HashimHayder and Peter O'Kane, MD explore drug-eluting balloon technology, minimizing metal, and clinical evidence supporting SELUTION SLR™ DEB in coronary intervention. Register now: tinyurl.com/nrcajmtf #CordisGoBeyond

SELUTION is here and headed to San Diego. SELUTION SLR™ Drug-Eluting Balloon is now FDA approved. Meet SELUTION at #TCT2026 and discover The Drug. The Data. The Delivery. Discover what we have planned and register for our events: tinyurl.com/p5btew36 #CordisGoBeyond

90.3% primary patency at 12 months. Late-breaking #SELUTION4SFA data demonstrated the highest reported 12-month primary patency in a U.S. SFA IDE randomized trial and superiority to plain balloon angioplasty. An important milestone as we work toward potential U.S. approval of SELUTION SLR SUSTANE™ DEB for femoropopliteal disease. Read more: ow.ly/oIyB50ZUUGw Investigational use only in the U.S. Not available for commercial sale. #VIVA2026 #PAD #SUSTANE

Less than a week away - late-breaking clinical data and expert discussion at #VIVA2026. Don't miss late-breaking clinical trial presentations on Monday, October 5, plus a #Cordis sponsored lunch symposium. • 8:10 AM PT – SELUTION4SFA RCT: 12-Month Results • 8:40 AM PT – SUCCESS PTA: 24-Month Data • 12:00–1:05 PM PT – Lunch Symposium Learn more about our peripheral clinical trials: tinyurl.com/bdhvu4z6 #CordisGoBeyond

Introducing our Early Adopters series: following the first interventional cardiologists and hospitals across the U.S. as they treat patients with in-stent restenosis (ISR) using newly FDA-approved SELUTION SLR™ Drug-Elution Balloon. Hear why these physicians are excited to be part of this early group. 🔗 Read more: ow.ly/tkZS50ZQBnr #SELUTIONSLR #InterventionalCardiology

Innovation recognized. Impact just beginning. Cordis and SELUTION SLR™ Drug-Eluting Balloon are proud to be recognized at the @PremierHA 2026 Supplier Innovation Celebration—honoring healthcare technologies making an impact on patient care. 🔗ow.ly/IXhp50ZSeEh #CordisGoBeyond #SELUTIONSLR

Heading to @CorsVascAtShore? SELUTION SLR™ Drug-Eluting Balloon (DEB) is now FDA approved. Join #Cordis for our breakfast symposium to learn more. 📅 Sept. 26 | 7–8 AM 📍 Seabright Room Learn more: tinyurl.com/rmpju8b9 #CordisGoBeyond

With FDA approval of the SELUTION SLR™ Drug-Eluting Balloon, Cordis becomes the first company to bring a sirolimus drug-eluting balloon to physicians and patients in the United States. 🔗 Full release: ow.ly/7N2x50ZQLH1 #SELUTIONSLR #InterventionalCardiology

FDA approved: the SELUTION SLR™ Drug-Eluting Balloon for coronary in-stent restenosis, the first and only sirolimus DEB in the U.S. 🔗 Full release: ow.ly/pmjs50ZORhW #SELUTIONSLR #InterventionalCardiology

New data. Live at #VIVA2026. 12-month results from the SELUTION4SFA FDA Study will be presented as late-breaking clinical data. 📅 Oct. 5 | 8:10 AM PT Presented by Principal Investigator @JayMathewsMD Explore the trial design ahead of the presentation: tinyurl.com/eycv9568 #CordisGoBeyond #SFA

Las Vegas, here we come! Join #Cordis at #VIVA2026: Oct. 5 | Late-Breaking Clinical Trials • 8:10 AM PT – SELUTION4SFA RCT: 12-Month Results • 8:40 AM PT – SUCCESS PTA: 24-Month Data Lunch Symposium | 12–1:05 PM PT Explore clinical data: bit.ly/4xdCEtv #CordisGoBeyond

☕ Take a moment for #CoffeeWithCordis. In Episode 8, Electrophysiology Technician Marketta Tanner shares her career journey and experience using the MYNX CONTROL® VENOUS Vascular Closure Device in a high-volume EP lab. Watch now: youtube.com/watch?v=hGqkzXNv… #CordisGoBeyond #Cordis

We're live at #CVI2026 in the Mile High City! Visit #Cordis at Booth #311 to explore the MYNX® Vascular Closure Portfolio. Explore our closure solutions: bit.ly/4hKq6Wg #CordisGoBeyond #MYNX

We're at #AMP2026! Visit the #Cordis team at Booth #300 to learn more about our peripheral vascular portfolio. Explore one of our peripheral solutions: cordis.com/na/products/saber… #CordisGoBeyond

We are proud to recognize our 2026 interns and the meaningful contributions they made across #Cordis. Their work supported our teams and helped advance our mission to transform cardiovascular care. #CordisGoBeyond #Internship

Beyond efficacy, what truly drives your confidence in a drug-coated technology? Join Dr. @AlokeFinn as he explores the evolution of DCB technology advancement from paclitaxel to sirolimus, comparing their pharmacokinetic profiles, mechanisms of action, and interactions within the coronary vasculature. Watch at #VuMedi to gain practical insights that can help inform your clinical decision-making. ow.ly/raXN50ZlNSQ #InterventionalCardiology #PCI #MedicalEducation

A quarter of a million patients. One philosophy: leave nothing behind. More than 250,000 patients worldwide have now been treated with SELUTION SLR™ Drug-Eluting Balloon, our sustained-release sirolimus drug-eluting balloon — a milestone that reflects the growing clinical confidence in #DEBfirst strategies across coronary #PCI and peripheral intervention. In a year defined by 250th milestones, ours is 250,000 reasons to keep advancing #InterventionalCardiology and endovascular care with technology designed to treat the lesion and leave no permanent implant behind. To every physician, investigator, and patient that trusted the technology — thank you. Explore the evidence behind #SELUTIONSLR cordis.com/emea/clinical-inf… SELUTION SLR DEB is approved in the United States for investigational use only. Not available for commercial use.

✨ Now published in @American_Heart #Circulation: 12-month results from the SELUTION DeNovo randomized trial. In 3,300+ patients across 62 international sites, a SELUTION SLR™ Drug-Eluting Balloon treatment strategy was non-inferior to systematic drug-eluting stent implantation for the study's primary endpoint at 12 months. 🔗ahajournals.org/doi/10.1161/… #CordisGoBeyond #SELUTIONSLR #InterventionalCardiology